Carmell Corp. Stock Plummets to New 52-Week Low of $1.12

Carmell Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.12 on September 16, 2025. This significant decline highlights the company's challenging performance over the past year, with a staggering drop of 53.5%, contrasting sharply with the S&P 500's gain of 17.58% during the same period.
The company's market capitalization stands at approximately USD 4 million, reflecting its microcap status. Notably, Carmell Corp. has not reported a price-to-earnings (P/E) ratio, indicating it is currently loss-making. The firm also has a debt-to-equity ratio of 0.39, suggesting a moderate level of leverage. Despite these financial metrics, the company boasts a remarkable return on equity of 152.26%, although its price-to-book ratio is negative at -1.20, indicating potential valuation concerns.

As Carmell Corp. navigates this challenging landscape, the recent price movement underscores the need for close monitoring of its operational and financial developments.